KalVista Pharmaceuticals, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 27 USD (At close: Jun 10, 2026) · Market cap 1.44B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
Details
| Name | KalVista Pharmaceuticals, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 275 |
| Ceo | Benjamin Palleiko |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US4834971032 |
| Cusip | 483497103 |
| Cik | 0001348911 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Benjamin L. Palleiko | Chief Executive Officer and Director |
| Brian Piekos | Chief Financial Officer |
| Bilal Arif | Chief Operating Officer |
| Dr. Paul K. Audhya M.B.A., M.D. | Chief Medical Officer |
| Ryan Baker | Head of Investor Relations |
| Brian Krex J.D. | General Counsel |
| Dr. Christopher L. Hamblett Ph.D. | Senior Vice President of Corporate Development |
| Linea Aspesi | Chief People Officer |
| Rachel M. Morten | Senior Vice President of Regulatory Affairs and QA |
| Dr. Christopher M. Yea Ph.D. | Chief Development Officer |
Contact
| Address | 200 Crossing Boulevard, Framingham, Massachusetts 01702, United States |
| Phone | 857 999 0075 |
| Website | https://www.kalvista.com |